2020年12月15日
SOMERSET, N.J., December 15, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021. Ying Huang, PhD, Chief Executive Officer and Chief Financial Officer of Legend Biotech, will present company updates on Wednesday, January 13, 2021 at 4:30 pm ET.
The webcast will be available to investors and other interested parties in the Events & Presentation section under Investors on Legend Biotech’s website at
https://investors.legendbiotech.com/events-and-presentations. A webcast replay will be available approximately 24-hrs after the live webcast.
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting -edge cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA targeted CAR-T cell therapy for patients with multiple myeloma. This candidate is currently being studied in registrational clinical trials. To learn more about Legend Biotech, visit us on LinkedIn, or on Twitter @LegendBiotech or at www.legendbiotech.com.
For Media and Investor Relations inquiries, please contact:
Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech
jessie.yeung@legendbiotech.com or investor@legendbiotech.com
Surabhi Verma, Manager of Investor Relations and Corporate Communications, Legend Biotech
Surabhi.verma@legendbiotech.com or media@legendbiotech.com
传奇生物公布2024年第三季度业绩及近期亮点
2024年11月12日
精彩预告 | 传奇生物CARTITUDE-4最新研究成果即将亮相2024ASH年会
2024年11月5日
传奇生物任命Alan Bash为CARVYKTI®总裁
2024年11月4日
传奇生物在费城新建先进的细胞治疗研发设施
2024年10月3日
传奇生物卡卫荻®(西达基奥仑赛注射液)在中国获批上市
2024年8月27日